{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:16:43Z","timestamp":1782782203178,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12032-018-1204-6","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T04:04:21Z","timestamp":1536638661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-8092","authenticated-orcid":false,"given":"Kathleen","family":"Nagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Palladino Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"1204_CR1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011. \n                    https:\/\/doi.org\/10.1182\/blood-2011-04-348540\n                    \n                  .","journal-title":"Blood"},{"key":"1204_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0406-4","author":"N Singh","year":"2016","unstructured":"Singh N, Frey NV, Grupp SA, Maude SL. CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol. 2016. \n                    https:\/\/doi.org\/10.1007\/s11864-016-0406-4\n                    \n                  .","journal-title":"Curr Treat Options Oncol"},{"key":"1204_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12602","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tan Y, Ou R, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol. 2016. \n                    https:\/\/doi.org\/10.1111\/ejh.12602\n                    \n                  .","journal-title":"Eur J Haematol"},{"key":"1204_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016. \n                    https:\/\/doi.org\/10.1172\/JCI85309\n                    \n                  .","journal-title":"J Clin Invest"},{"key":"1204_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3008226\n                    \n                  .","journal-title":"Sci Transl Med"},{"key":"1204_CR6","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines)\u2014acute lymphoblastic leukemia. 2014. Version 1. \n                    http:\/\/williams.medicine.wisc.edu\/all.pdf\n                    \n                  . Accessed 15 Dec 2017."},{"key":"1204_CR7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008. \n                    https:\/\/doi.org\/10.1182\/blood-2007-06-093906\n                    \n                  .","journal-title":"Blood"},{"key":"1204_CR8","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines)\u2014non-Hodgkin\u2019s lymphoma. 2014. Version 4.2014. \n                    https:\/\/www.nccn.org\/about\/nhl.pdf\n                    \n                  . Accessed 15 Dec 2017."},{"key":"1204_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-552729\n                    \n                  .","journal-title":"Blood"},{"key":"1204_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009. \n                    https:\/\/doi.org\/10.1136\/bmj.b2700\n                    \n                  .","journal-title":"BMJ"},{"key":"1204_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1407222\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1204_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1709866\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1204_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aac5415\n                    \n                  .","journal-title":"Sci Transl Med"},{"issue":"3","key":"1204_CR14","first-page":"397","volume":"93","author":"SL Ramer","year":"2005","unstructured":"Ramer SL. Site-ation pearl growing: methods and librarianship history and theory. J Med Libr Assoc. 2005;93(3):397\u2013400.","journal-title":"J Med Libr Assoc"},{"key":"1204_CR15","unstructured":"U.S. Department of Health & Human Services. Agency for Healthcare Research and Quality. Systematic review data repository. \n                    https:\/\/srdr.ahrq.gov\/\n                    \n                  . Accessed 11 Aug 2018."},{"key":"1204_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011. \n                    https:\/\/doi.org\/10.1136\/bmj.d5928\n                    \n                  .","journal-title":"BMJ"},{"key":"1204_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1799","author":"Y Hu","year":"2017","unstructured":"Hu Y, Wu Z, Luo Y, et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1799\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"1204_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017. \n                    https:\/\/doi.org\/10.1182\/blood-2017-02-769208\n                    \n                  .","journal-title":"Blood"},{"key":"1204_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3\n                    \n                  .","journal-title":"Lancet"},{"key":"1204_CR20","unstructured":"OpenMeta[Analyst]. \n                    http:\/\/www.cebm.brown.edu\/openmeta\/\n                    \n                  . Accessed 11 Aug 2018."},{"key":"1204_CR21","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). 2010. \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\n                    \n                  . Accessed 15 Dec 2017."},{"key":"1204_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Eng J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1709919\n                    \n                  .","journal-title":"N Eng J Med"},{"key":"1204_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-018-0019-6","author":"KL Lowe","year":"2018","unstructured":"Lowe KL, Mackall CL, Norry E, et al. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018. \n                    https:\/\/doi.org\/10.1038\/s41434-018-0019-6\n                    \n                  .","journal-title":"Gene Ther"},{"key":"1204_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","volume":"25","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243\u201351.","journal-title":"J Immunother"},{"issue":"5","key":"1204_CR25","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","volume":"111","author":"V Pullarkat","year":"2008","unstructured":"Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of the Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563\u201372.","journal-title":"Blood"},{"key":"1204_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"CH Pui","year":"2004","unstructured":"Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Eng J Med. 2004;350:1535\u201348.","journal-title":"N Eng J Med"},{"key":"1204_CR27","first-page":"3310","volume":"95","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310\u201322.","journal-title":"Blood"},{"key":"1204_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547\u201361.","journal-title":"J Clin Oncol"},{"key":"1204_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/cncr.11664","volume":"98","author":"S Faderl","year":"2003","unstructured":"Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337\u201354.","journal-title":"Cancer"},{"key":"1204_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009. \n                    https:\/\/doi.org\/10.1038\/mt.2009.83\n                    \n                  .","journal-title":"Mol Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1204-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1204-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1204-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T19:27:39Z","timestamp":1568143659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1204-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1204-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"18 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"144"}}